March 29, 2018 Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
March 12, 2018 Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition
February 6, 2018 Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference
December 14, 2017 Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
December 11, 2017 Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
December 4, 2017 Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
November 14, 2017 Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights